Bioline RX

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. Its pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is a immunotherapy treatment used fro multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

TEL AVIV, Israel , July 17, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers and rare diseases, today announced the initiation of a randomized, investigator-initiated Phase 2 clinical trial in first line metastatic pancreatic cancer based on preliminary data from the single-arm pilot phase.

BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide

A PDUFA date of September 9, 2023 has been established for review of Motixafortide for Autologous Transplantation in Multiple Myeloma. Results from a phase 2 Columbia University investigator study, using Motixafortide in combination with LIBTAYO + SOC chemotherapy for first-line metastatic PDAC patients, are expected to be released in 2023. Initiation of a phase 2b study partnered with Genfleet, using Motixafortide + PD-1 inhibitor + SOC chemotherapy for first-line metastatic PDAC patients, is expected in 2023.

BioLineRx: PDUFA Catalyst And PDAC Advancement Make This Worth A Look

CRISPR Therapeutics

Viking Therapeutics

Now is a great time to accumulate top undervalued biotech stocks. For one, the sector is recession-proof.

The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023

Elevation Oncology

Lumber Liquidators

View

Vroom

If you're like many retail traders in the stock market today, penny stocks are a popular prospect. This article looks at some of the most active penny stocks today with late-breaking momentum.

5 Penny Stocks To Watch Before Next Week; Time To Buy?

BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2023 Earnings Conference Call May 24, 2023 10:00 AM ET Company Participants John Lacey - Investor Relations Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly May - Chief Commercial Officer Ella Sorani - Chief Development Officer Tami Rachmilewitz - Chief Medical Officer Conference Call Participants Joe Pantginis - H.C.

BioLineRx Ltd. (BLRX) Q1 2023 Earnings Call Transcript

On Track for September PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM)  Rapidly Advancing U.S. Commercial Activities in Support of Potential September Launch  Announced Publication in Nature Medicine of GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in SCM for Autologous Transplantation in MM  Management to hold conference call today, May 24, at 10:00 am EDT  TEL AVIV, Israel , May 24, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported its unaudited financial results for the first quarter ended March 31, 2023, and provided corporate and portfolio updates.

BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

Management to Hold Conference Call at 10:00 a.m. EDT TEL AVIV, Israel , May 17, 2023 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx to Report First Quarter 2023 Results on May 24, 2023

Cue Biopharma

Precigen

Sana Biotechnology

Ardelyx

Atossa Genetics

Corvus Pharmaceuticals

Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.

7 High-Potential Penny Stocks in the Biotech Sector

TEL AVIV, Israel , April 25, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

TEL AVIV, Israel, April 17, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced the publication of data from the Company's GENESIS Phase 3 clinical trial in the peer-reviewed journal Nature Medicine. The international GENESIS trial evaluated the safety and efficacy of the Company's lead investigational candidate motixafortide plus granulocyte colony-stimulating factor (G-CSF) versus placebo plus G-CSF for the mobilization of hematopoietic stem cells in patients with multiple myeloma prior to autologous stem cell transplantation (ASCT).

BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma

Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided.

The 3 Best Biotech Stocks Under $1 to Buy for April

BioLineRx Ltd. (NASDAQ:BLRX ) Q4 2022 Earnings Conference Call March 22, 2023 10:00 AM ET Company Participants John Lacey - Investor Relations Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly May - Chief Commercial Officer Ella Sorani - Chief Development Officer Conference Call Participants Mark Breidenbach - Oppenheimer Joe Pantginis - Wainwright John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.

BioLineRx Ltd. (BLRX) Q4 2022 Earnings Call Transcript

- Announced FDA Acceptance of APHEXDA® (motixafortide) New Drug Application (NDA) in Stem Cell Mobilization with Prescription Drug User Fee Act (PDUFA) Target Action Date of September 9, 2023 - - Named Tami Rachmilewitz, M.D., as new Chief Medical Officer and Completed Formation of U.S. Commercial Leadership Team with Extensive Drug Launch and Sales Experience  - - Entered into Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease  - - Management to hold conference call today, March 22, at 10:00 am EDT - TEL AVIV, Israel , March 22, 2023 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates

Management to Hold Conference Call at 10:00 am EDT TEL AVIV, Israel , March 15, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it will release its audited financial results for the year ended December 31, 2022 on Wednesday, March 22, 2023, before the U.S. markets open.

BioLineRx to Report 2022 Annual Financial Results on March 22, 2023

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022, both dates inclusive (the “Class Period”), of the important March 6, 2023 lead plaintiff deadline. SO WHAT: If you purchased BioLine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

BLRX FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm – BLRX

- Clinical trial part of long-term growth strategy for motixafortide across multiple potential therapeutic areas - TEL AVIV, Israel , March 6, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced a collaboration with Washington University School of Medicine in St. Louis to advance a Phase 1 clinical trial that will evaluate the safety and feasibility of the Company's lead clinical candidate motixafortide to mobilize CD34+ hematopoietic stem cells (HSCs) for gene therapies in sickle cell disease (SCD), one of the most common genetic diseases globally.

BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

NEW YORK , March 4, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022, both dates inclusive (the "Class Period"), of the important  March 6, 2023 lead plaintiff deadline.

BLRX MONDAY DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm - BLRX

NEW YORK , March 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioLineRx Ltd. ("BioLineRx" or the "Company") (NASDAQ: BLRX).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioLineRx Ltd. - BLRX

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 6, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired BioLineRx Ltd. (“BioLine” or the “Company”) (NASDAQ: BLRX) American Depositary Shares (“ADSs”) between February 23, 2021 and September 19, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioLineRx Ltd.

LOS ANGELES , March 2, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against BioLineRx Ltd.

BLRX Investors Have Opportunity to Lead BioLineRx Ltd. Securities Fraud Lawsuit

NEW YORK , Feb. 25, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022, both dates inclusive (the "Class Period"), of the important  March 6, 2023 lead plaintiff deadline.

BLRX IMPORTANT DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages BioLineRx Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm - BLRX

NEW YORK , Feb. 18, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022, both dates inclusive (the "Class Period"), of the important  March 6, 2023 lead plaintiff deadline.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX

New York, New York--(Newsfile Corp. - February 17, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022, both dates inclusive (the "Class Period"), of the important March 6, 2023 lead plaintiff deadline.

ROSEN, GLOBALLY RECOGNIZED LAW FIRM, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX

NEW YORK , Feb. 11, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022, both dates inclusive (the "Class Period"), of the important  March 6, 2023 lead plaintiff deadline.

ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages BioLineRx Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX

New York, New York--(Newsfile Corp. - February 10, 2023) - Pomerantz LLP is investigating claims on behalf of investors of BioLineRx Ltd. ("BioLineRx" or the "Company") (NASDAQ: BLRX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether BioLineRx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

News for Bioline RX Stock (BLRX)